In 1998 ZymeTx licensed Oklahoma Medical Research Foundation (OMRF) technology to develop a new preclinical HIV treatment. ZymeTx, Inc. was a biotechnology company engaged in the development of products for the diagnosis and treatment of viral disease, viral management, and disease surveillance. ZymeTx's ZstatFlu influenza diagnostic used enzymes to make viral infections visible to the naked eye in about 20 minutes. ZstatFlu can be administered in a doctor's office, so patients can be diagnosed and receive treatment faster. Initially traded on NASDAQ and then OTC, after two mild flu seasons hindered sales, in 2002 ZymeTx filed for Chapter 11 bankruptcy. The firm continued to operate at some level but when it emerged from bankruptcy, in 2005 the firm sold to CT-based DiagXotics, Inc. its ZstatFlu inventory and licensed the rights to most of its assets including its National Flu Surveillance Network, which tracks flu outbreaks across the US
